You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Clinical Update on B-Cell Maturation Antigen-Directed Therapies for Multiple Myeloma

  • Authors: Thomas Martin, MD; Charise Gleason, MSN, NP-C, AOCNP; Saad Usmani, MD, MBA, FACP
  • CME / ABIM MOC / CE Released: 5/17/2023
  • Valid for credit through: 5/17/2024
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Nurses - 1.00 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

    IPCE - 1.00 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for community-based hematologists/oncologists, nurses/nurse practitioners, and pharmacists.

The goal of this activity is for learners to be better able to evaluate the value of BCMA as a therapeutic target for the treatment of MM and to integrate BCMA-directed therapies into clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanisms of action of BCMA-directed therapies
    • Clinical trial data evaluating BCMA-directed therapies for the treatment of MM
  • Have greater competence related to
    • Managing adverse events (AEs) of BCMA-directed therapies as part of an interprofessional care team
  • Demonstrate greater confidence in their ability to
    • Integrate BCMA-directed therapies into clinical practice


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Thomas Martin, MD

    Professor of Clinical Medicine
    Director
    Adult BMT
    Co-Director
    Myeloma Program
    Helen Diller Family Comprehensive Cancer Center
    University of California San Francisco
    San Francisco, California

    Disclosures

    Thomas Martin, MD, has the following relevant financial relationships: 
    Consultant or advisor for: GlaxoSmithKline
    Research funding from: Amgen Inc.; Janssen Biotech, Inc.; Sanofi 

  • Charise Gleason, MSN, NP-C, AOCNP

    Adjunct Faculty
    Nell Hodgson Woodruff School of Nursing
    Advanced Practice Provider Chief
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

    Disclosures

    The opinions expressed are those of Charise Gleason, MSN, NP-C, AOCNP and do not necessarily reflect the views of Emory University or Emory Healthcare. Charise Gleason’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

    Charise Gleason, MSN, NP-C, AOCNP, has no relevant financial relationships.

  • Saad Usmani, MD, MBA, FACP

    Chief of Myeloma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Saad Usmani, MD, MBA, FACP, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; Edo Pharma; Genentech; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Oncopeptides AB; Sanofi; Secura Bio; Seagen, Inc.; SkylineDX; Takeda Pharmaceuticals U.S.A., Inc.; TeneoBio 
    Research funding from: Amgen Inc.; Array BioPharma; Bristol Myers Squibb Company; Celgene Corporation; GlaxoSmithKline; Janssen Biotech, Inc.; Merck; Pharmacyclics, Inc.; Sanofi; Seagen, Inc.; SkylineDX; Takeda Pharmaceuticals U.S.A., Inc.

Editors

  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC

    Disclosures

    Megan Whitney, DMD, has no relevant financial relationships.  

  • Tristin Abair, PhD

    Senior Medical Writer, Medscape, LLC  

    Disclosures

    Tristin Abair, PhD, has no relevant financial relationships.  

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-23-186-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Clinical Update on B-Cell Maturation Antigen-Directed Therapies for Multiple Myeloma

Authors: Thomas Martin, MD; Charise Gleason, MSN, NP-C, AOCNP; Saad Usmani, MD, MBA, FACPFaculty and Disclosures

CME / ABIM MOC / CE Released: 5/17/2023

Valid for credit through: 5/17/2024

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Current Status of BCMA-Directed Antibody-Drug Conjugates in MM

Dr Martin discusses clinical perspectives related to BCMA-targeted ADCs in the treatment of MM.
Thomas Martin, MD

Making Strides With BCMA-Targeted CAR T Cells

Charise Gleason provides expert insight on the optimal use of CAR T cells in MM.
Charise Gleason, MSN, NP-C, AOCNP

The Promise of BCMA-Targeted Bispecific Antibodies in R/R MM

Get the latest updates from Dr Usmani on bispecific antibodies targeting BCMA in MM.
Saad Usmani, MD, MBA, FACP
 

Educational Impact Challenge

The goal of this activity is for learners to be better able to evaluate the value of B-cell maturation antigen (BCMA) as a therapeutic target for the treatment of multiple myeloma (MM) and to integrate BCMA-directed therapies into clinical practice.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print